


Alzheimer's Disease Research Study

Nicotinamide (NA)

Alzheimer's disease and histone deacetylase inhibitors (HDAC)

Specific enzymes, known as HDAC, in the brain have been shown to regulate tumor suppression, as well as inhibit gene promoters. These are known as HDAC inhibitors. HDAC inhibitors are beginning to be studied in neurodegenerative diseases (like Alzheimer's disease) to see if these enzymes can help improve brain function.



What is nicotinamide (NA)?

Nicotinamide (NA) is a class of drugs known as a HDAC inhibitor, a dietary supplement that is being studied to determine whether chronic use is safe and effective in improving brain function in subjects with mild to moderate Alzheimer's disease (AD). NA, also known as vitamin B3, is a natural substance that is currently sold in health food stores. We do not yet know whether the use of NA can help prevent or slow the course of Alzheimer's disease and the U.S. Food and Drug Administration (FDA) has not approved NA for the treatment of AD. We will also be studying the effect of NA on a specific protein, called phospho-tau (AT180), in the spinal fluid, and whether this can be used as a "biomarker" to track or predict memory problems.

The Nicotinamide Study

The **Department of Neurology and the Institute for Brain Aging and Dementia** at the **University of California, Irvine** is launching a study to find out more about Nicotinamide and its effects on Alzheimer's disease progression. Participants will be assessed regularly by physicians and qualified health care professionals during the study.

The Nicotinamide study is seeking volunteers who:

- Have a diagnosis of probable AD
- Are 50 years of age or older
- Have a study partner – friend or relative who can accompany the participant to all clinic visits and answer questions about him/her
- Are willing to take either study supplement or placebo

This study is a randomized, placebo-controlled 7-month study. There are 7 total visits to the UC Irvine campus. Visits are every 2-6 weeks.

For more information, please call:

Beatriz Yañez
(949) 824-5733

University of California, Irvine
Institute for Brain Aging and Dementia
1100 Gottschalk Medical Plaza
Irvine, CA 92697-4285